Access to the pregnancy sickness medication Xonvea in the United Kingdom is determined by local Integrated Care Boards (ICBs), resulting in a "postcode lottery" for pregnant individuals seeking the drug. While Xonvea is included in the formulary for Hampshire and the Isle of Wight, it is not universally a first-line treatment option.
Neil Hardy, Chief Pharmacist for NHS Hampshire and Isle of Wight, stated that Xonvea is available as a treatment option for nausea and vomiting in pregnancy but is not currently the preferred first-line choice. It can be considered for patients who have not responded to or are not suitable for other antiemetic treatments. Hardy acknowledged that experiences in accessing medicines can differ and welcomed the move towards a national formulary to improve consistency across the NHS.
Jasmeen Basi, a patient who was prescribed Xonvea by her GP, experienced a seven-week wait to obtain the medication. Eldridge, a representative advocating for wider access, highlighted the difficulties in obtaining Xonvea and called for equal access for all women in the UK who wish to try the medication.
A spokesperson for the Department of Health and Social Care confirmed that decisions regarding prescriptions, including Xonvea, are made by the doctor responsible for the patient's care. The department is working towards a Single National Formulary, as outlined in the 10-Year Health Plan, which aims to ensure more equitable access to medicines nationwide.